GNC-077

Phase 1Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

GNC-077 is one of 92 small molecule programs targeting Gastrointestinal Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal TumorsNot yet recruiting

Lung CancerRecruiting

Breast CancerRecruiting

Gastrointestinal TumorsPhase 1

Not yet recruiting

Lung CancerPhase 1

Recruiting

Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Breast Cancer

NCT06609187

Phase 1Recruiting

Lung Cancer

NCT06612840

Q4 2027

Phase 1Not yet recruiting

Gastrointestinal Tumors

NCT06755242

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06609187·20 enrolled

Gastrointestinal Tumors1 trial

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06755242·20 enrolled

Lung Cancer1 trial

A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06612840·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GNC-077. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNC-077 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNC-077. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

GNC-077

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Breast Cancer1 trial

Gastrointestinal Tumors1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News